The Hygiology Post is presenting information about a company that seems to have much potential to help many people. Both 2012 and 2013 appear to be pivotal years in determining how helpful the patented technologies may actually be for people.
Senesco Technologies has continued to update information on its web site (https://www.senesco.com/; obtained on 01-13-13). As a matter of disclosure : The author continues to be a current shareholder in the company.
The site, ClinicalTrials.gov (https://clinicaltrials.gov/show/NCT01435720; obtained on 01-13-13), shows a study that is sponsored by “Senesco Technologies, Inc.” and is described as “Safety and Tolerability Study of SNS01-T in Relapsed or Refractory Multiple Myeloma, Mantle Cell Lymphoma, or Diffuse Large B Cell Lymphoma”. It also shows that “This study is currently recruiting participants.” The study is currently in Phase I and Phase II. “The purpose of this study is to determine how well SNS01-T is tolerated by relapsed or refractory multiple myeloma, mantle cell lymphoma or diffuse large B cell lymphoma patients when given by intravenous infusion at various doses.”
Recruitment locations are : The University of Arkansas for Medical Sciences, The Mayo Clinic, Hackensack University Medical Center, and West Virginia University Mary Babb Randolf Cancer Center.
The reader can go to The ClinicalTrials.gov (https://clinicaltrials.gov/show/NCT01435720; obtained on 01-13-13) web site to obtain more detailed information.
The Hygiology Post ® welcomes feedback from readers as to whether the articles (individually and/or collectively) help fulfill its vision and mission.
Louis DeCola, Jr. © 2013 The Hygiology Post ®